Drug intelligence / Profile preview

KG-2019

Development stage: Unknown
Lead developer: JN Nova Pharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

KG-2019 is a novel fusion protein drug candidate developed by JN Nova Pharma. It is classified as an immunomodulator and was designed as a therapeutic for COVID-19, with potential applications in other infectious and respiratory diseases. The molecule acts by modulating the immune response, though specific molecular targets are not detailed in public sources. Preclinical data suggest it may function as an ACE2 decoy, potentially trapping and inhibiting SARS-CoV-2 viral entry into host cells[1][2][6]. As of the latest updates, its highest development phase is preclinical.

Other names: KG2019KG-2019KG 2019

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on KG-2019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KG-2019.

Explore the full profile